Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AWAKE: Ravulizumab for Prevention and Reduction of Delayed Graft Function After Kidney Transplantation
2024-517568-48-00Phase 3Authorised
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in delayed graft function (DGF) comparing Ravulizumab (Ultomiris) with Placebo (Anti C5 Complement mAb Placebo) (2 arms). Primary endpoint: Time to freedom from dialysis through 90 days post-transplant. Planned start Jul 2025; status: authorised.
02
Drugs
ravulizumab
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on 2024-517568-48-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517568-48-00.